$ZYME News

How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing Deal

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Zymeworks stock surges on $813M Roche licensing deal

Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow

Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est

Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M

Wolfe Research Initiates Coverage On Zymeworks with Outperform Rating

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript